BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oxxon Therapeutics Inc. Reports Positive Preliminary Phase IIa Data With Chronic Hepatitis B Therapeutic Vaccine


11/11/2005 10:44:43 AM

Oxxon Therapeutics, Inc. announced today that data would be presented at the 56th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) on Monday November 14th in a plenary session. Oxxon will present positive interim data from a Phase IIa, 52-week study of its novel therapeutic vaccine comprising a PrimeBoost immunotherapeutic approach in patients with chronic hepatitis B. The study, which was conducted in two parts, found the therapy was safe and generally well tolerated. Overall, these data show that at 14 weeks, Oxxon's PrimeBoost immunotherapy alone elicited hepatitis B antigen loss in 9/40 (23%) of patients as compared to only 1/11 (9%) of those who received lamivudine alone. In addition, no patient receiving lamivudine had seroconverted by week 14 whereas 5/40 (13%) of patients having received immunotherapeutic alone had done so. This seroconversion rate was sustained to at least week 26 - longer-term follow up continues.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES